TrialHuman vaccines & immunotherapeutics2023

Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18-49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors.

Laura L Hammitt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.